{"id":"nct:NCT05872620","kind":"trial","title":"A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes","authors":["Eli Lilly and Company"],"author_count":1,"year":2023,"published":"2023-05-24","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT05872620","source_url":"https://clinicaltrials.gov/study/NCT05872620","archive_url":"https://space-kitty.com/papers/nct:NCT05872620","updated":"2026-09-04","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Obesity","Overweight","Type 2 Diabetes"],"details":{"acronym":"ATTAIN-2","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1613,"sponsor":"Eli Lilly and Company","conditions":["Obesity","Overweight","Type 2 Diabetes"],"interventions":["DRUG: Orforglipron","DRUG: Placebo"],"start_date":"2023-06-05","start_date_type":"ACTUAL","primary_completion_date":"2025-08-08","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[{"slug":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/glp1-metabolic"}]}